Interest in remote patient monitoring is intensifying in the wake of the COVID-19 pandemic, as more healthcare shifts to home-based settings. This is the first in a series of articles on the future of RPM and how both established competitors and innovative start-ups are working to meet growing demand for remote care technologies. First up: a discussion with James Mault, MD, co-founder and CEO of BioIntelliSense.
Telemedicine and remote patient monitoring (RPM) have been pushed to the forefront during the COVID-19 health emergency and companies that operate in this field are experiencing unprecedented growth and demand for their products and services. As the pandemic accelerates the ongoing move toward digital health, a variety of remote care options will be needed to meet future demand. That opens the door not only for existing RPM competitors but also for a growing number of consumer tech companies and medtech start-ups seeking to make an impact in the remote healthcare marketplace with technologies ranging from fitness wearables to implantable sensors.